Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021).

[1]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[2]  J. Pedro-Botet,et al.  Reconocer la obesidad como enfermedad: todo un reto , 2020, Revista Clínica Española.

[3]  D. Rabi,et al.  Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - The User's Guide. , 2020, Canadian journal of diabetes.

[4]  K. Khunti,et al.  KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2020, Kidney international.

[5]  K. Khunti,et al.  Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study , 2020, Diabetes, obesity & metabolism.

[6]  I. Lingvay,et al.  Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis , 2020, The Journal of clinical endocrinology and metabolism.

[7]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[8]  B. Zinman,et al.  Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. , 2020, Journal of hypertension.

[9]  D. Panagiotakos,et al.  Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). , 2020, European journal of preventive cardiology.

[10]  A. Franco‐Cereceda,et al.  Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis , 2020, Circulation.

[11]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[12]  Deepak L. Bhatt,et al.  Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. , 2020, Circulation.

[13]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[14]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[15]  S. Bain,et al.  Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes , 2020, Current medical research and opinion.

[16]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[17]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[18]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[19]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[20]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[21]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[22]  Farzane Sivandzade,et al.  Public Health Policies on E-Cigarettes , 2019, Current Cardiology Reports.

[23]  M. Sabatine,et al.  SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply , 2019, The Lancet.

[24]  A. Mazza,et al.  The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension , 2019, High Blood Pressure & Cardiovascular Prevention.

[25]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[26]  A. Scheen.  Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view. , 2019, Diabetes research and clinical practice.

[27]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[28]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[29]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[30]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[31]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[32]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[33]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[34]  P. Whelton,et al.  Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT , 2018, Journal of the American Heart Association.

[35]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[36]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[37]  N. Cook,et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.

[38]  J. Ascaso,et al.  Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. , 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[39]  Rohini Sharma,et al.  Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis , 2018, Current medical research and opinion.

[40]  Changgui Shi,et al.  Effect of continuous positive airway pressure on glucose metabolism in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials , 2018, Sleep and Breathing.

[41]  N. Kerse,et al.  Interventions to improve the appropriate use of polypharmacy for older people. , 2018, The Cochrane database of systematic reviews.

[42]  D. Aguilar,et al.  Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus , 2017, Current Heart Failure Reports.

[43]  J. Salemi,et al.  Multimorbidity is associated with increased rates of depression in patients hospitalized with diabetes mellitus in the United States. , 2017, Journal of diabetes and its complications.

[44]  I. Gouni-Berthold.  The efficacy of anti-PCSK9 antibodies: Results from recent trials. , 2017, Atherosclerosis. Supplements.

[45]  K. Khunti,et al.  The prevalence of diabetes‐specific emotional distress in people with Type 2 diabetes: a systematic review and meta‐analysis , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[46]  E. Antonucci,et al.  Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome , 2017, PloS one.

[47]  Hachidai Takahashi,et al.  The impact of serum trans fatty acids concentration on plaque vulnerability in patients with coronary artery disease: Assessment via optical coherence tomography. , 2017, Atherosclerosis.

[48]  T. Pilgrim,et al.  Dual antiplatelet therapy for secondary prevention of coronary artery disease , 2017, Open Heart.

[49]  J. Mckenney,et al.  Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). , 2017, The American journal of cardiology.

[50]  F. Hobbs,et al.  Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease , 2017, PloS one.

[51]  Y. L. Koh,et al.  Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study , 2017, BMJ Open.

[52]  T. Cui,et al.  Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients , 2017, Medicine.

[53]  Audrey Y. Chu,et al.  Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol , 2017, Journal of the American Heart Association.

[54]  T. Abbruscato,et al.  Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is Metformin a viable countermeasure? , 2017, Redox biology.

[55]  B. Zinman,et al.  Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.

[56]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[57]  R. Kalyani,et al.  Reducing CV risk in diabetes: An ADA update. , 2017, The Journal of family practice.

[58]  K. Lam,et al.  CPAP therapy for patients with sleep apnea and type 2 diabetes mellitus improves control of blood pressure , 2017, Sleep and Breathing.

[59]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[60]  G. Watts,et al.  Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) , 2017, Circulation.

[61]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[62]  M. Kosiborod.  Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. , 2017, Journal of diabetes and its complications.

[63]  Maoqin Shu,et al.  Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. , 2017, The Cochrane database of systematic reviews.

[64]  R. Beaser,et al.  Insulin: Making Sense of Current Options. , 2016, Endocrinology and metabolism clinics of North America.

[65]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[66]  L. Cucullo,et al.  A decade of e-cigarettes: Limited research & unresolved safety concerns. , 2016, Toxicology.

[67]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[68]  R. Plodkowski,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[69]  Ji-Guang Wang,et al.  The J-Curve Phenomenon in Hypertension , 2016, Pulse.

[70]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[71]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[72]  M. Musella,et al.  Efficacy of Bariatric Surgery in Type 2 Diabetes Mellitus Remission: the Role of Mini Gastric Bypass/One Anastomosis Gastric Bypass and Sleeve Gastrectomy at 1 Year of Follow-up. A European survey , 2016, Obesity Surgery.

[73]  J. Pedro-Botet,et al.  [Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9]. , 2016, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[74]  N. Plana,et al.  Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60 , 2016 .

[75]  S. Bangalore,et al.  Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials , 2016, British Medical Journal.

[76]  R. Giugliano,et al.  Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.

[77]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[78]  G. Watts,et al.  Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. , 2015, International journal of cardiology.

[79]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[80]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[81]  E. Ortega,et al.  Diabetes mellitus y riesgo cardiovascular: recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015) , 2015, Atencion primaria.

[82]  J. Mckenney.  Understanding PCSK9 and anti-PCSK9 therapies. , 2015, Journal of clinical lipidology.

[83]  P. Poulsen,et al.  Targeting Nocturnal Hypertension in Type 2 Diabetes Mellitus , 2014, Hypertension.

[84]  M. Teresa.,et al.  Ejercicio físico y salud , 2014 .

[85]  K. Maki,et al.  Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia , 2014, Expert review of cardiovascular therapy.

[86]  M. Tonelli,et al.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.

[87]  D. Lorber.  Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus , 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

[88]  P. Iglesias,et al.  Diabetes mellitus y enfermedad renal en el anciano , 2014 .

[89]  A. Goday,et al.  Impact of Different Criteria on Type 2 Diabetes Remission Rate After Bariatric Surgery , 2014, Obesity Surgery.

[90]  S. Madsbad,et al.  Bariatric surgery - effects on obesity and related co-morbidities. , 2014, Current diabetes reviews.

[91]  P. Ridker,et al.  An assessment by the Statin Diabetes Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[92]  D. Dyakov,et al.  Statin-associated incident diabetes: a literature review. , 2014, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[93]  P. Iglesias,et al.  Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain). , 2014, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

[94]  Jbs Board.  Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[95]  R. Glasgow,et al.  Reductions in Regimen Distress Are Associated With Improved Management and Glycemic Control Over Time , 2014, Diabetes Care.

[96]  A. Schwartz,et al.  Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study , 2014, Obesity.

[97]  H. Wijeysundera,et al.  Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. , 2013, JAMA.

[98]  X. Shu,et al.  Dietary carbohydrates, refined grains, glycemic load, and risk of coronary heart disease in Chinese adults. , 2013, American journal of epidemiology.

[99]  C. Mangione,et al.  Guidelines Abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update , 2013, Journal of the American Geriatrics Society.

[100]  Daniel E Forman,et al.  Exercise standards for testing and training: a scientific statement from the American Heart Association. , 2013, Circulation.

[101]  J. French,et al.  Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial. , 2013, Clinical therapeutics.

[102]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[103]  Richard Taylor,et al.  Is there a dose-response relation of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of prospective cohort studies. , 2013, The American journal of clinical nutrition.

[104]  E. Haut,et al.  The Eastern Association of the Surgery of Trauma approach to practice management guideline development using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology , 2012, The journal of trauma and acute care surgery.

[105]  M. Elia,et al.  Malnutrition self-screening by using MUST in hospital outpatients: validity, reliability, and ease of use. , 2012, The American journal of clinical nutrition.

[106]  F. Arrieta,et al.  Influencia de la pérdida de peso en la evolución clínica, metabólica y psicológica de los pacientes con sobrepeso u obesidad , 2012 .

[107]  S. Blair,et al.  Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy , 2012, BDJ.

[108]  P. Ridker,et al.  On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). , 2012, Journal of the American College of Cardiology.

[109]  E. Boyko,et al.  Associations Among Visceral Fat, All-Cause Mortality, and Obesity-Related Mortality in Japanese Americans , 2012, Diabetes Care.

[110]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[111]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[112]  Daniel Umpierre,et al.  Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. , 2011, JAMA.

[113]  P. Wilson,et al.  Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation , 2010, Circulation.

[114]  Renee F Wilson,et al.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. , 2008, Archives of internal medicine.

[115]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[116]  D. Coyle,et al.  Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes , 2007, Annals of Internal Medicine.

[117]  A. King,et al.  Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. , 2007, Medicine and science in sports and exercise.

[118]  Frank M. Sacks,et al.  Dietary Approaches to Prevent and Treat Hypertension: A Scientific Statement From the American Heart Association , 2006, Hypertension.

[119]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[120]  F. Sacks.  The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. , 2001, The American journal of cardiology.

[121]  N. Grishin,et al.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.

[122]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[123]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[124]  J. Pedro-Botet,et al.  Therapeutic Approach with PCSK9 Inhibitors for Effective Cardiovascular Risk Reduction in Diabetes , 2021, Cardiology and Cardiovascular Medicine.

[125]  V. Barrios,et al.  [Chronic kidney disease and dyslipidaemia]. , 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[126]  S. Conway,et al.  Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine. , 2017, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[127]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[128]  Evolocumab (Repatha)--A Second PCSK9 Inhibitor to Lower LDL-Cholesterol. , 2015, JAMA.

[129]  M. Elisaf,et al.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? , 2013, The review of diabetic studies : RDS.

[130]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[131]  B. Swinburn,et al.  Pharmaceutical utilisation and costs before and after bariatric surgery , 2013, International Journal of Obesity.

[132]  J. M. L. Bejarano,et al.  Recomendaciones sobre la detección, seguimiento y criterios de derivación de la enfermedad renal crónica en el ámbito de la Comunidad de Madrid , 2012 .

[133]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[134]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[135]  S. Haffner.  Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.